---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045133"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:03:35.027411+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anebulo Pharma Q1 net loss narrows to $2.2M; awarded $1.9M NIDA grant for selonabant

## Summary
- Net loss of $2.2M ($0.08/sh) vs $2.5M ($0.10/sh) in prior year quarter.
- Operating expenses of $2.4M, down from $2.5M year-over-year.
- Cash $1.4M at Sept 30, 2024; access to $10M loan facility.
- Awarded $1.9M NIDA grant to support IV selonabant development.
- Plans to enroll first healthy volunteer in IV study in first half of 2025.

## SEC filing metadata
- accession: 0001493152-24-045133
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315224045133/0001493152-24-045133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315224045133/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045133
- JSON: https://secwatch.observer/filing/0001493152-24-045133.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.